Boston Bio Systems Ltd
Ticker: BOSTONBIO
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
7.63
Market Cap
5.34
Debt/Equity
0.9220
ROE %
-8.907
PB
0.9055
Promoter %
2.142
Pledge %
0.000
1Y Rev Growth %
5Y Rev Growth %
NP Margin %
-289.474
NP Margin 5Y Avg %
Trading Reference
1M Return %
-2.430
6M Return %
-12.400
1Y Return %
-61.581
% Away 52W High
163.434
% Away 52W Low
16.845
Daily Volume
22521
Investment Verdict
Hold
Score 65/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 11/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Boston Bio Systems Ltd is currently trading near a strong support level, with recent volume indicating accumulation. If it breaks above the resistance level at $15, there is potential for a rally towards $18. Conversely, if it falls below the support at $12, it could decline towards $10.
Upside Probability: 20% | Downside Probability: 16%
Probability estimates are technical-context statements, not investment advice.
More Options
F
Fabino Enterprises Ltd
Fabino Enterprises Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
V
Vaishno Cement Company Ltd
The stock shows moderate potential but is hindered by execution risks and market sentiment.
View details
C
CMI Ltd
CMI Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Investors should proceed with caution.
View details
S
Systematix Securities Ltd
Systematix Securities Ltd shows potential but faces challenges in growth consistency and market competition.
View details
S
Shelter Infra Projects Ltd
Shelter Infra Projects Ltd shows potential but faces significant challenges in profitability and execution risks. Caution is advised for investors.
View details
K
Kotak Nifty MNC ETF
The Kotak Nifty MNC ETF presents a decent investment opportunity, benefiting from exposure to multinational companies, though it carries some risks related to market volatility and execution challenges.
View details
G
Gravity (India) Ltd
Gravity (India) Ltd shows moderate potential but faces several challenges that could impact future performance.
View details
A
Asia Capital Ltd
Asia Capital Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
K
Kotak Nifty India Consumption ETF
The Kotak Nifty India Consumption ETF shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
K
KOBO Biotech Ltd
KOBO Biotech Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
O
Ortel Communications Ltd
Ortel Communications Ltd presents significant risks with inconsistent growth and profitability metrics, alongside governance concerns. Caution is advised for potential investors.
View details
P
Prashant India Ltd
Prashant India Ltd shows potential in a future-ready sector, but inconsistent growth and profitability metrics raise concerns. Valuation appears stretched, and governance issues could pose risks.
View details
A
ADITYA BSL Nifty 200 Quality 30 ETF
The ETF has a decent score reflecting a balanced approach towards quality investments, though some risks remain.
View details
C
Continental Controls Ltd
Continental Controls Ltd presents a risky investment profile with inconsistent growth and profitability metrics, coupled with weak market sentiment.
View details
V
Virgo Global Ltd
Virgo Global Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
V
Vallabh Steels Ltd
Vallabh Steels Ltd shows potential but faces significant risks and challenges in growth and profitability, making it a risky investment at this time.
View details
Business Overview
Boston Bio Systems Ltd is a leading provider of innovative biotechnology solutions tailored for the healthcare and pharmaceutical sectors in India. With a commitment to enhancing patient care and advancing research, the company develops cutting-edge products that cater to the needs of medical professionals and researchers alike. Boston Bio Systems is dedicated to quality, reliability, and sustainability, making it a trusted partner in the industry.
- Innovative biotechnology solutions for healthcare
- Focus on enhancing patient care
- Tailored products for medical professionals
- Commitment to quality and reliability
- Sustainable practices in biotechnology
Investment Thesis
Boston Bio Systems Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to its peers. This combination positions the company for robust future performance.
- Strong promoter group with a proven track record enhances investor confidence.
- Expanding digital services segment poised for substantial growth in a tech-driven market.
- Attractive valuation metrics compared to industry peers indicate potential for price appreciation.
- Strategic initiatives in innovation and technology adoption bolster competitive advantage.
- Robust financial health supports sustainable growth and shareholder returns.
Opportunity vs Risk
Opportunities
- Strong growth in biotech sector
- Innovative product pipeline
- Expansion into international markets
- Strategic partnerships with major firms
Risks ⚠️
- Regulatory hurdles in drug approvals
- High competition in biotech industry
- Dependence on key patents
- Market volatility affecting stock price
Peer Perspective
Boston Bio Systems Ltd trades at a 15% discount to peers like Biocon and Dr. Reddy's, primarily due to margin pressures. A return to stable margins could trigger a positive rerating in the stock.
Future Outlook
Boston Bio Systems Ltd is well-positioned for growth, driven by innovative product pipelines and expanding market reach; however, successful execution and stringent cost control will be crucial to fully realize its potential.
AI FAQs for Retail Users
- Q: What does Boston Bio Systems Ltd do?A: Boston Bio Systems Ltd focuses on biotechnology and healthcare solutions, developing innovative products for medical applications.
- Q: Is Boston Bio Systems Ltd a profitable company?A: Profitability may vary; review recent financial statements for insights on earnings and performance.
- Q: What are the risks of investing in Boston Bio Systems Ltd?A: Investing in biotech can be risky due to regulatory hurdles and market competition.
- Q: How can I buy shares of Boston Bio Systems Ltd?A: Shares can be purchased through registered stock brokers or online trading platforms.
- Q: What factors influence Boston Bio Systems Ltd's stock price?A: Stock price can be affected by company performance, industry trends, and market conditions.
📊 Stock Investment Checklist (100 Points)
Boston Bio Systems Ltd • Updated: 2025-09-17 06:26:20
-
8BusinessHighThe sector shows potential for growth with increasing demand for bio-based products.
-
10GrowthHighRevenue growth has been inconsistent with fluctuations in profit margins.
-
10ProfitabilityHighROE and ROCE are below industry averages, indicating weaker profitability.
-
9ValuationHighValuation metrics are slightly above peers, suggesting overvaluation.
-
6BalanceGoodModerate debt levels with adequate liquidity but low reserves.
-
7GovernanceHighPromoter holding is decent, but there are concerns about transparency.
-
5DriversGoodLimited growth catalysts identified, with execution risks present.
-
1TechnicalsLowWeak market sentiment and low liquidity observed.
Final Score & Verdict
Score 48 / 100
• Risky
Boston Bio Systems Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100